Looking Forward to #ASTRO24 in DC The Evolution of Cancer within a Patient: Tumor Phylogenetics and Implications for Local Therapy James Yu, MD Is there a Subset of Prostate Cancer Patients Who are Unlikely to Benefit from SBRT to Prostate and/or Oligo-métastases?

Sean Collins Prostate SBRT @Tampa General Hospital 🌻🌳🌺 J Nic Fisk 🌺🌳🌻 will drop some knowledge at this session!

Looking Forward to #ASTRO24 in DC! Management of Small Cell Neuroendocrine Tumors of the Genitourinary Tract Omar Mian, MD Any Benefit to Local RT?

Bonus: Vedang Murthy, MD from Tata Memorial Discussing RT for Rare Varient GU Cancers!

Amazing Job Brian!

My New Hobby: Watching Cruise Ships Exit Ybor Harbor in Tampa!

Are there Adequate Numbers of CTCs in Nodal Oligo recurrent Prostate Cancer to Make this Clinically Useful? Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing… pubmed.ncbi.nlm.nih.gov/39239745/

Sean Collins Prostate SBRT @Tampa General Hospital Fascinating study on CTCs in oligorecurrent hormone-sensitive prostate cancer patients! The correlation between high CTC counts and distant progression-free survival is striking.

Go USF Bulls!

PACE A: SBRT was associated with less urinary incontinence and sexual dysfunction, and slightly more bowel bother than prostatectomy. Full study link: europeanurology.com/article/S0302-…

RADIANT trial out now IJROBP - The Red Journal - In patients with oligoprogressive GU, breast & GI cancers treated with SBRT, >50% remain on same line systemic therapy at a year. More analyses to come Aisling Barry Joelle Radiation Medicine Program authors.elsevier.com/sd/article/S03…

Sean Collins Prostate SBRT @Tampa General Hospital showed that even patients with severe LUTS can be treated with #SBRT and many have improved symptoms after! Sean can you share the ref pls?

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate S… pubmed.ncbi.nlm.nih.gov/32719744/

Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androge… pubmed.ncbi.nlm.nih.gov/38781786/

Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate … pubmed.ncbi.nlm.nih.gov/39271420/